Article

Billionaire Mark Cuban Advocates for Lower Drug Prices

Mark Cuban pushes to stop pharmaceutical manufacturers from price gouging.

Rising pharmaceutical costs are a problem that has gained significant attention recently, prompting concern among individuals at all income levels. Mark Cuban, billionaire entrepreneur and owner of the NBA’s Dallas Mavericks, recently expressed interest in stopping pharmaceutical companies from price gouging.

“I’m all for capitalism at its purest, but it requires capitalists acting like human beings first,” Cuban wrote in an email to STAT. “If they don’t, the cost of health care goes up for everyone to the point where we can’t afford insurance and people die or receive inadequate care.”

Cuban said that major stakeholders such as shareholders, insurers, and the general population need to pressure these companies to reduce prices or face legislation that could reduce their profits. Although Cuban is not an expert in the pharmaceutical market, he recognizes the enormous investment potential in pharmaceuticals, since it is an area that will always be a high priority.

Cuban said in the interview with STAT there are changes that could be made to reduce costs, such as the proposals in a Harvard Business Review article he recently Tweeted with the caption: “It’s time to bring drug pricing under control. Empathy arbitrage cannot be a pricing strategy.”

The article discusses different issues with the pharmaceutical market, and even briefly addresses the presumptive Presidential candidate’s health plans, previously reported on by AJPB. Cuban also suggests government-issued exclusivities that include the extension of drugs that could potentially reduce costs.

Critics of these ideas could argue that these companies will stop producing life-saving drugs, but Cuban disagrees.

“This is how they make their money,” he told STAT. “They will be smarter about how they spend their money, but they can’t stop spending because it means they won’t make as much.”

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © Andrey Popov - stock.adobe.com